GC
BDTX icon

Globeflex Capital’s Black Diamond Therapeutics BDTX Stock Holding History

Globeflex Capital’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-305,276
Closed -$650K – 401
2026
Q1 		$650K Hold
305,276
– – 0.1% 204
2025
Q4 		$742K Hold
305,276
– – 0.11% 191
2025
Q3 		$1.16M Buy
+305,276
New +$893K 0.18% 146

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Globeflex Capital's BDTX Position: Q2 2026 in Review

Globeflex Capital sold out of Black Diamond Therapeutics (BDTX) in Q2 2026, closing a stake of 305,276 shares — an estimated $650K sold.

Globeflex Capital first reported a position in BDTX in Q3 2025 and held it in 3 quarters. The position peaked at $1.16M in Q3 2025. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Globeflex Capital reported no remaining Black Diamond Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Globeflex Capital sold 305,276 Black Diamond Therapeutics shares in Q2 2026, an estimated $650K.
  • Globeflex Capital first reported a position in Black Diamond Therapeutics in Q3 2025 and held it in 3 quarters.
  • Globeflex Capital's Black Diamond Therapeutics position peaked at $1.16M in Q3 2025.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Globeflex Capital's 13F filing for Q2 2026, filed 12 Aug 2026.